var data={"title":"Deferoxamine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Deferoxamine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5984?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=deferoxamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Deferoxamine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=deferoxamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Deferoxamine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157271\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Desferal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157272\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Deferoxamine Mesylate for Injection;</li>\n      <li>Desferal;</li>\n      <li>PMS-Deferoxamine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157313\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote;</li>\n      <li>\n        Chelating Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157274\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute iron toxicity: </b> <b>Note:</b> The IV route is preferred and is used when severe toxicity is evidenced by cardiovascular collapse or systemic symptoms (coma, shock, metabolic acidosis, or gastrointestinal bleeding) or potentially severe intoxications (peak serum iron level &gt;500 mcg/dL) (Perrone 2015). The IM route may be used (per the manufacturer) but is not preferred and rarely indicated. The use of deferoxamine in situations in which the peak serum iron concentration is &lt;500 mcg/dL or when severe toxicity is not evident is a subject of clinical debate (Howland 2015; Perrone 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: Initial: 1,000 mg, may be followed by 500 mg every 4 hours for 2 doses; subsequent doses of 500 mg have been administered every 4 to 12 hours based on clinical response (maximum recommended dose: 6,000 mg/day [per manufacturer])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic iron overload: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: 500 to 1,000 mg/day (maximum: 1000 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 40 to 50 mg/kg/day (maximum: 60 mg/kg/day) over 8 to 12 hours for 5 to 7 days per week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: 1,000 to 2,000 mg/day or 20 to 40 mg/kg/day over 8 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing:</i> IV, SubQ: 25 to 50 mg/kg over 8 to 10 hours 5 to 7 days per week (Brittenham, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnosis of aluminum-induced toxicity with CKD (off-label use) (K/DOQI guidelines 2003):</b> IV: Test dose: 5 mg/kg during the last hour of dialysis if baseline serum aluminum concentrations are 60 to 200 mcg/L, or clinical signs/symptoms of toxicity, or aluminum exposure prior to parathyroid surgery. Measure aluminum just prior to deferoxamine; remeasure 2 days later (test is positive if serum aluminum increases by &ge;50 mcg/L). Do not use if unstimulated aluminum serum concentrations are &gt;200 mcg/L to avoid deferoxamine-induced neurotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of aluminum toxicity with CKD (off-label use) (K/DOQI guideline, 2003):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Administer after diagnostic deferoxamine test dose. <b>Note:</b> The risk for deferoxamine-associated neurotoxicity is increased if unstimulated aluminum serum concentrations are &gt;200 mcg/L; do not perform the deferoxamine-stimulation test and administer intensive dialysis until &lt;200 mcg/L.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>If the serum aluminum concentration rises to &ge;300 mcg/L two days after the deferoxamine test dose <b>or</b> there are side effects after the deferoxamine-stimulation test:</i> 5 mg/kg once a week 5 hours before dialysis for 4 months. Then discontinue deferoxamine for one month and perform the deferoxamine-stimulation test again.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>If the serum aluminum concentration is &lt;300 mcg/L two days after the deferoxamine test dose <b>and </b>there are no side effects after the deferoxamine-stimulation test:</i> 5 mg/kg once a week during the last hour of dialysis for 2 months. The discontinue deferoxamine for one month and perform the deferoxamine-stimulation test again.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157293\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=deferoxamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Deferoxamine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute iron toxicity: </b> Children and Adolescents: <b>Note:</b> The IV route is preferred and is used when severe toxicity is evidenced by cardiovascular collapse or systemic symptoms (coma, shock, metabolic acidosis, or gastrointestinal bleeding) or potentially severe intoxications (peak serum iron level &gt;500 mcg/dL) (Perrone 2015). The IM route may be used (per the manufacturer) but is not preferred and rarely indicated. The use of deferoxamine in situations in which the peak serum iron concentration is &lt;500 mcg/dL or when severe toxicity is not evident is a subject of clinical debate (Howland 2015; Perrone 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: 90 mg/kg/dose every 8 hours (maximum: 6,000 mg/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 15 mg/kg/hour (maximum: 6,000 mg/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic iron overload: </b> Children &ge;3 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 20 to 40 mg/kg/day over 8 to 12 hours for 5 to 7 days per week; dose should not exceed 40 mg/kg/day until growth has ceased</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: 20 to 40 mg/kg/day over 8 to 12 hours (maximum: 1,000 to 2,000 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing:</i> IV, SubQ: 25 to 30 mg/kg over 8 to 10 hours 5 to 7 days per week (Brittenham, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnosis of aluminum induced toxicity with CKD (off-label use) (K/DOQI guidelines 2003):</b> Children and Adolescents: IV: Test dose: 5 mg/kg during the last hour of dialysis if baseline serum aluminum concentrations are 60 to 200 mcg/L, or clinical signs/symptoms of toxicity, or aluminum exposure prior to parathyroid surgery. Measure aluminum just prior to deferoxamine; remeasure 2 days later (test is positive if serum aluminum increases by &ge;50 mcg/L). Do not use if unstimulated aluminum serum concentrations are &gt;200 mcg/L to avoid deferoxamine-induced neurotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of aluminum toxicity with CKD (off-label use) (K/DOQI guidelines 2003):</b> Children and Adolescents: IV: Administer after diagnostic deferoxamine test dose. <b>Note:</b> The risk for deferoxamine-associated neurotoxicity is increased if unstimulated aluminum serum concentrations are &gt;200 mcg/L; do not perform the deferoxamine-stimulation test and administer intensive dialysis until &lt;200 mcg/L.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>If the serum aluminum concentration rises to &ge;300 mcg/L two days after the deferoxamine test dose <b>or</b> there are side effects after the deferoxamine-stimulation test:</i> 5 mg/kg once a week 5 hours before dialysis for 4 months. Then discontinue deferoxamine for one month and perform the deferoxamine-stimulation test again.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>If the serum aluminum concentration is &lt;300 mcg/L two days after the deferoxamine test dose <b>and </b>there are no side effects after the deferoxamine-stimulation test:</i> 5 mg/kg once a week during the last hour of dialysis for 2 months. The discontinue deferoxamine for one month and perform the deferoxamine-stimulation test again.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157275\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. May initiate at the lower end of the dosing range.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157276\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Severe renal disease or anuria: Use is contraindicated in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The following adjustments have been used by some clinicians (Aronoff 2007): Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;50 mL/minute: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 50 mL/minute, CRRT: Administer 25% to 50% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl&lt;10 mL/minute, hemodialysis, peritoneal dialysis: Avoid use</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13811880\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157252\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as mesylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Desferal: 500 mg (1 ea); 2 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 2 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157237\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157255\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Urticaria, flushing of the skin, hypotension, and shock have occurred following rapid IV administration; limiting infusion rate to 15 mg/kg/hour may help avoid infusion-related adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acute iron toxicity: The IV route is generally preferred in patients with severe toxicity (ie, patients in shock). For the first 1,000 mg, infuse at 15 mg/kg/hour (although rates up to 40 to 50 mg/kg/hour have been given in patients with severe iron intoxication). Subsequent doses may be given over 4 to 12 hours at a rate not to exceed 125 mg/hour.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chronic iron overload: Administer over 8 to 12 hours for 5 to 7 days per week; rate not to exceed 15 mg/kg/hour. In patients with poor compliance, deferoxamine may be administered on the same day of blood transfusion, either prior to or following transfusion; do not administer concurrently with transfusion. Longer infusion times (24 hours) and IV administration may be required in patients with severe cardiac iron deposition (Brittenham, 2011). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diagnosis or treatment of aluminum-induced toxicity with CKD: Administer dose over 1 hour, during the last hour of dialysis (K/DOQI guidelines, 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">SubQ: When administered for chronic iron overload, administration over 8 to 12 hours using a portable infusion pump is generally recommended; however, longer infusion times (24 hours) may also be used. Topical anesthetic or glucocorticoid creams may be used for induration or erythema (Brittenham, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: IM administration may be used for patients with acute iron toxicity that do not exhibit severe symptoms (per the manufacturer), but the IV route is preferred (Perrone 2015); may also be used in the treatment of chronic iron toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157253\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute iron toxicity: </b>Adjunct in the treatment of acute iron intoxication</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic iron overload: </b>Treatment of chronic iron overload secondary to multiple transfusions (often due to the presence of thalassemia major or sickle cell disease [Borgna-Pignatti 2015; Marsella 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475164\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Diagnosis or treatment of aluminum-induced toxicity associated with chronic kidney disease (CKD)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157321\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Deferoxamine may be confused with cefuroxime, deferasirox, deferiprone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Desferal may be confused with desflurane, Desyrel, Dexferrum</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Desferal [U.S., Canada, and multiple international markets] may be confused with Deseril brand name for methysergide [Australia, Belgium, Great Britain, Netherlands]; Disophrol brand name for dexbrompheniramine and pseudoephedrine [Czech Republic, Poland, Turkey]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157244\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Flushing, hypotension, shock, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Brain disease (aluminum toxicity/dialysis-related), dizziness, headache, neuropathy (peripheral, sensory, motor, or mixed), paresthesia, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Growth suppression (children), hyperparathyroidism (aggravated), hypocalcemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal distress, abdominal pain, diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Dysuria, urine discoloration (reddish  color)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Dysplasia (metaphyseal; children &lt;3 years; dose related), leukopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Hepatic insufficiency, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis (with or without shock), angioedema, hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Infection (<i>Yersinia</i>, mucormycosis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reaction (burning, crust, edema, erythema, eschar, induration, infiltration, irritation, pain, pruritus, swelling, vesicles, wheal formation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, muscle spasm, myalgia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Blurred vision, cataract, chromatopsia, corneal opacity, decreased peripheral vision, decreased visual acuity, nocturnal amblyopia, optic neuritis, retinal pigment changes, scotoma, vision loss, visual field defect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Hearing loss, tinnitus </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Acute renal failure, increased serum creatinine, renal tubular disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Acute respiratory distress (dyspnea, cyanosis, and/or interstitial infiltrates), asthma </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157258\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to deferoxamine or any component of the formulation; patients with severe renal disease or anuria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157241\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acute respiratory distress syndrome (ARDS): Deferoxamine has been associated with ARDS following excessively high-dose IV treatment of acute iron intoxication or thalassemia; has been reported in children and adults. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Auditory effects: Auditory disturbances (tinnitus and high frequency hearing loss) have been reported following prolonged administration, at high doses, or in patients with low ferritin levels; effects are generally reversible with early detection and immediate discontinuation. Elderly patients are at increased risk for hearing loss. Audiology exams are recommended with long-term treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Growth retardation: High deferoxamine doses and concurrent low ferritin levels are also associated with growth retardation. Growth velocity may partially resume to pretreatment rates after deferoxamine dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infection: Patients with iron overload are at increased susceptibility to infection with <i>Yersinia enterocolitica</i> and <i>Yersinia pseudotuberculosis;</i> treatment with deferoxamine may enhance this risk; if infection develops, discontinue therapy until resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infusion reactions: Flushing of the skin, hypotension, urticaria, and shock are associated with rapid IV infusion; administer by slow IV infusion, IM, or slow subcutaneous infusion only.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Mucormycosis: Rare and serious cases of mucormycosis (including fatalities) have been reported with use; withhold treatment with signs and symptoms of mucormycosis. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ocular effects: Ocular disturbances (blurred vision; cataracts; corneal opacities; decreased visual acuity; impaired peripheral, color, and night vision; optic neuritis; retinal pigment abnormalities; retinopathy; scotoma; visual loss/defect) have been reported following prolonged administration, at high doses, or in patients with low ferritin levels; effects are generally reversible with early detection and immediate discontinuation. Elderly patients are at increased risk for ocular disorders. Periodic ophthalmic exams are recommended with long-term treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal effects: Increases in serum creatinine, acute renal failure and renal tubular disorders have been reported; monitor for changes in renal function. Deferoxamine is readily dialyzable. When iron is chelated with deferoxamine, the chelate is water-soluble and is excreted renally.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Urine discoloration: Patients should be informed that urine may have a pink, reddish, or orange discoloration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aluminum toxicity: Treatment with deferoxamine in patients with aluminum toxicity may cause hypocalcemia and aggravate hyperparathyroidism. Deferoxamine may cause neurological symptoms (including seizure) in patients with aluminum-related encephalopathy receiving dialysis and may precipitate dialysis dementia onset.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemochromatosis: Deferoxamine is <b>not</b> indicated for the treatment of primary hemochromatosis (treatment of choice is phlebotomy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ascorbic acid: Combination treatment with ascorbic acid (&gt;500 mg/day in adults) and deferoxamine may impair cardiac function (rare), effects are reversible upon discontinuation of ascorbic acid. If combination treatment is warranted, initiate ascorbic acid only after one month of regular deferoxamine treatment, do not exceed ascorbic acid dose of 200 mg/day for adults (in divided doses), 100 mg/day for children &ge;10 years of age, or 50 mg/day in children &lt;10 years of age; monitor cardiac function. Do not administer deferoxamine in combination with ascorbic acid in patients with preexisting cardiac failure. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299129\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157246\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9327&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ascorbic Acid: May enhance the adverse/toxic effect of Deferoxamine. Left ventricular dysfunction is of particular concern. Management: Avoid ascorbic acid doses greater than 200 mg/day.  Lower doses may be given to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump.  Monitor cardiac function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Deferoxamine. Management: Avoid ascorbic acid doses greater than 200 mg/day.  Lower doses may be given to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump.  Monitor cardiac function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Deferoxamine. Left ventricular dysfunction is of particular concern. Management: Avoid ascorbic acid doses greater than 200 mg/day.  Lower doses may be given to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump.  Monitor cardiac function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the adverse/toxic effect of Deferoxamine. Management: Avoid ascorbic acid doses greater than 200 mg/day.  Lower doses may be given to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump.  Monitor cardiac function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prochlorperazine: Deferoxamine may enhance the adverse/toxic effect of Prochlorperazine. Specifically, prolonged loss of consciousness has been reported. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157248\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802788\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">Adverse events have been observed in animal reproduction studies. Toxic amounts of iron or deferoxamine have not been noted to cross the placenta; however, the metabolic effects of a maternal overdose may adversely affect the fetus. In case of acute iron toxicity, treatment during pregnancy should not be withheld (Chang 2011). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13811879\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if deferoxamine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering to nursing women. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802790\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">Vitamin C supplements may need to be limited. The manufacturer recommends a maximum ascorbic acid dose of 200 mg/day in adults (given in divided doses), 100 mg/day in children &ge;10 years of age, or 50 mg/day in children &lt;10 years of age. Avoid concurrent use with ascorbic acid in patients with heart failure. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157250\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum iron, ferritin, total iron-binding capacity, CBC with differential, renal function tests (serum creatinine), liver function tests, serum chemistries; ophthalmologic exam (visual acuity tests, fundoscopy, slit-lamp exam) and audiometry with long-term treatment; growth and body weight in children (every 3 months). When deferoxamine complexes with iron it forms a water-soluble compound (ferrixoamine) that imparts discoloration of the urine; often described as vin ros&eacute; (dark pink) discoloration to the urine (Fern&aacute;ndez 2014). However, other than being aware of that it may occur, its presence or absence should not be used as a therapeutic endpoint.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Dialysis patients: Serum aluminum (yearly; every 3 months in patients on aluminum-containing medications)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aluminum-induced bone disease: Serum aluminum concentration 2 days following deferoxamine test dose; test is considered positive if the serum aluminum increases &ge;50 mcg/L</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802987\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron, serum: Normal: 50 to 160 mcg/dL; peak levels &gt;500 mcg/dL may be associated with toxicity. Consider treatment in symptomatic patients with levels &ge;350 mcg/dL; toxicity cannot be excluded with serum iron levels &lt;350 mcg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aluminum, serum: &lt;20 mcg/L recommended baseline level in dialysis patients (K/DOQI 2003)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157240\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Complexes with trivalent ions (ferric ions), primarily in the vascular space, to form ferrioxamine, which is eliminated in the urine by the kidneys. One hundred milligrams of deferoxamine will bind about 8.5 mg of free circulating elemental iron (85 mg per 1,000 mg dose) but does not remove iron from transferrin or hemoglobin. Binding of cytoplasmic free iron reduces the free iron-induced disruption of mitochondrial cell membranes and enzyme systems. Ferrioxamine may create a pink- to red- or orange-colored urine as it is being excreted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157257\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM, SubQ: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributed throughout body fluids</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &lt;10%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Plasma enzymes; binds with iron to form ferrioxamine (iron complex)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 14 hours; plasma: 20 to 30 minutes (Brittenham 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine (as unchanged drug and ferrioxamine); feces (via bile)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157260\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Deferoxamine Mesylate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $49.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $15.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Desferal Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $40.86</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157261\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Desferal (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CU, CY, CZ, DE, DK, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HN, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JM, JO, KE, KR, KW, LB, LK, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, OM, PH, PK, PL, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Desferin (ES);</li>\n      <li>Talifer (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allain P, Mauras Y, Chaleil D, et al, &ldquo;Pharmacokinetics and Renal Elimination of Desferrioxamine and Ferrioxamine in Healthy Subjects and Patients With Haemochromatosis,&rdquo; <i>Br J Clin Pharmacol</i>, 1987, 24(2):207-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/3620295/pubmed\" target=\"_blank\" id=\"3620295\">3620295</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 116.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bacon BR, Adams PC, Kowdley KV, et al, &ldquo;Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Disease,&rdquo; <i>Hepatology</i>, 2011, 54(1):328-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/21452290/pubmed\" target=\"_blank\" id=\"21452290\">21452290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borgna-Pignatti C, Marsella M. Iron Chelation in Thalassemia Major. <i>Clin Ther</i>. 2015;37(12):2866-2877.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/26519233/pubmed\" target=\"_blank\" id=\"26519233\">26519233</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brittenham GM. &ldquo;Iron-Chelating Therapy for Transfusional Iron Overload,&rdquo; <i>N Engl J Med</i>, 2011, 364(2):146-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/21226580/pubmed\" target=\"_blank\" id=\"21226580\">21226580</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chang TPY and Rangan C, &ldquo;Iron Poisoning-A Literature-Based Review of Epidemiology, Diagnosis, and Management,&rdquo; <i>Pediatr Emerg Care</i>, 2011, 27(10):978-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/21975503/pubmed\" target=\"_blank\" id=\"21975503\">21975503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Desferal (deferoxamine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fern&aacute;ndez S, Castro P, Nogu&eacute; S, Nicol&aacute;s JM. Acute iron intoxication: change in urine color during chelation therapy with deferoxamine. <i>Intensive Care Med</i>. 2014;40(1):104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/24072332/pubmed\" target=\"_blank\" id=\"24072332\">24072332</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howland MA. Antidotes in depth. <i>Goldfrank's Toxicologic Emergencies</i>. 10th ed. Hoffman RS, Howland MA, Lewin NA, et al, eds. New York, NY: McGraw-Hill; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 6. Serum Calcium and Calcium-Phosphorus Product.&rdquo; Available at http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide6.htm14520607</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lawson MK, Valko M, Cronin MT, Jomov&aacute; K. Chelators in Iron and Copper Toxicity. <i>Curr Pharmacol Rep.</i> 2016;2(6):271-280.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marsella M, Borgna-Pignatti C. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease. <i>Hematol Oncol Clin North Am</i>. 2014;28(4):703-727.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/25064709/pubmed\" target=\"_blank\" id=\"25064709\">25064709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perrone J. Iron. <i>Goldfrank's Toxicologic Emergencies</i>. 10th ed. Hoffman RS, Howland MA, Lewin NA, et al, eds. New York, NY: McGraw-Hill; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sheth S. Iron chelation: an update. <i>Curr Opinion Hematol</i>. 2014;21(3):179-185.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/24504090/pubmed\" target=\"_blank\" id=\"24504090\">24504090</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stiles ML, Allen LV, and Prince SJ, &ldquo;Stability of Deferoxamine Mesylate, Floxuridine, Fluorouracil, Hydromorphone Hydrochloride, Lorazepam, and Midazolam Hydrochloride in Polypropylene Infusion-Pump Syringes,&rdquo; <i>Am J Health Syst Pharm</i>, 1996, 53(13):1583-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/8809281/pubmed\" target=\"_blank\" id=\"8809281\">8809281</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valentine K, Mastropietro C, and Sarnaik AP, &ldquo;Infantile Iron Poisoning: Challenges in Diagnosis and Management,&rdquo; <i>Pediatr Crit Care Med</i>, 2009, 10(3):e31-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/19433938/pubmed\" target=\"_blank\" id=\"19433938\">19433938</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9327 Version 123.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F157271\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F157272\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F157313\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F157274\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F157293\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F157275\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F157276\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13811880\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F157252\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F157237\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F157255\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F157253\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475164\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F157321\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F157244\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F157258\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F157241\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299129\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F157246\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F157248\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F802788\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13811879\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F802790\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F157250\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F802987\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F157240\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F157257\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F157260\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F157261\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9327|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=deferoxamine-patient-drug-information\" class=\"drug drug_patient\">Deferoxamine: Patient drug information</a></li><li><a href=\"topic.htm?path=deferoxamine-pediatric-drug-information\" class=\"drug drug_pediatric\">Deferoxamine: Pediatric drug information</a></li></ul></div></div>","javascript":null}